Summary of presentations at a satellite symposium that took place on 14th April 2016 as a part of the International Liver Congress (ILC) 2016 organised by the European Association for the Study of the Liver (EASL) in Barcelona, Spain
Chairpersons: Heiner Wedemeyer,1 Ira Jacobson2,3
Speakers: Heiner Wedemeyer,1 Robert S. Brown, Jr.,2 Antonio Craxí,4 Ira Jacobson2,3
1. Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
2. Department of Medicine, Weill Cornell Medical College, New York, New York, USA
3. Department of Medicine, Mount Sinai Beth Israel Hospital, New York, New York, USA
4. Department of Internal Medicine, University of Palermo, Palermo, Italy
Disclosure: Professor Wedemeyer has received honoraria for consulting or speaking from Abbott, AbbVie, Biolex, BMS, Boehringer Ingelheim, Gilead, ITS, JJ/Janssen-Cilag, Medgenics, Merck/ScheringPlough, Novartis, Roche, Roche Diagnostics, Siemens, Transgene, and ViiV. He has also received research grants from Abbott, BMS, Gilead, Merck, Novartis, Roche, Roche Diagnostics, and Siemens. Professor Brown has received grants and consulting honoraria from AbbVie, Gilead, BMS, Janssen, and Merck. Professor Craxi has received honoraria as a speaker or a member of speakers’ bureau, or as an advisor or consultant, or has received grants for clinical research from Abbott, AbbVie, Achillion, Bayer, BMS, Boehringer Ingelheim, Gilead, JJ/Janssen-Cilag, Merck/Schering-Plough, Novartis, Roche, and Roche Diagnostics. Professor Jacobson has received grant/research support from AbbVie, BMS, Gilead, Merck, and Janssen. He is also a member of speakers’ bureaux for AbbVie, BMS, Gilead, Janssen, and Intercept, and has received consultant/advisor honoraria from AbbVie, BMS, Gilead, Janssen, Merck, Trek, and Intercept.
Acknowledgements: Writing assistance was provided by Kabira Alieva of ApotheCom.
Support: The symposium was sponsored by AbbVie. Authors received honoraria for preparation and delivery of their presentations. The views and opinions expressed are those of the authors and not necessarily of AbbVie.
Disclaimer: The contents of this summary of presentations contain information regarding pharmaceutical products or indications that are currently not approved. The information is provided for scientific purposes only, and shall not be in any way construed as a recommendation for use of any of these products or indications. Please refer to the appropriate package inserts for approved indications.
Citation: EMJ Hepatol. 2016;4:32-40.
The symposium addressed the efficacy and safety of compounds currently available for treatment of hepatitis C virus (HCV) and chronic kidney disease (CKD) in North American and European countries, comparing data from trials and clinical practice. Prof Wedemeyer opened the meeting with a discussion of real-world experiences, with a focus on HCV genotypes (GTs) and resistance-associated variants (RAV). Prof Brown concentrated on trial and real-world data from patients with advanced liver disease, while Prof Craxí’s presentation focussed on chronic kidney conditions and infection. Prof Jacobson led the question and answer session and summarised the discussions.